Kornimate/medical-research-clean huggingface dataset:
obstructive sleep apnoea post covid 19: role of the upper airway microbiome

Conditions: Sleepiness; SARS-CoV2 Infection; Fatigue Syndrome, Chronic; Snoring

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) causing coronavirus disease, covid-19, has spread rapidly across the globe since its emergence in january 2020. as of january 2021, there are 87.6 million confirmed cases worldwide, with 1.9milion deaths. in conjunction with this high disease incidence, there have also been reports of covid-19 related sleep disordered breathing, with up 18% in a chinese study and 57% in an italian study of individuals with covid-19 reporting sleep disturbance. obstructive sleep apnea (osa) is a common, chronic condition due to partial or complete upper airway collapse during sleep. osa is more common in males \& obese individuals, both of which are more adversely affected by sars-cov-2 infection. furthermore, inflammation of the upper airway, or nasal passages leading to congestion could lead to a compromised upper airway during sleep and subsequently, obstructive sleep apnea. we believe that's sars -cov-2 infection, and subsequent covid-19 will lead to an altered microbiome in the upper airway. this is turn will lead to worsening nasal inflammation and congestion, which could predispose individual with previous covid-19 disease to osa. additionally, osa is treated with continuous positive airway pressure (cpap) a machine which delivers pressurized air into the upper airway via a face mask. this keeps the upper airway open during sleep. when cpap is well tolerated by individuals, it works well to reduce the symptoms of osa. unfortunately, many patients find it difficult to tolerate cpap. one reason often reported for poor tolerance is nasal congestion. we believe that an altered upper airway microbiome, due to previous sars-cov-2 infection, will affect treatment adherence to cpap therapy. secondly, we will investigate if treatment with cpap therapy causes any change in the upper airway microbiome.


Eligibility criteria:
inclusion criteria: * symptoms of sleepiness, fatigue, loud snoring exclusion criteria: 1. gross skeletal alterations affecting the upper airway (eg.micrognathia) 2. unstable chronic medical conditions known to affect osa (chf, stroke) 3. 3. pregnancy or intent to become pregnant within the period of the protocol 4. inability to sign informed consent form 5. habitual snorer or previous diagnosis of osa. 6. less than 18 years of age.

Keywords: sars-cov2 microbiome obstructive sleep apnea
randomized comparison of continuous and intermittent heparin infusion during catheter ablation of atrial fibrillation

Conditions: Coagulation; Intravascular

Summary: optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important. randomized comparison of continuous and intermittent heparin infusion during catheter ablation of atrial fibrillation.

intravenous heparin was used during the procedure to prevent catheter-induced thrombosis. heparin is administered during the procedure to achieve recommended activation clotting times (act) values, typically \>300 seconds to prevent thromboemboli during the procedure. most of the practitioners was that act level should be checked at 30- to 60-minute intervals and then have injected intermittently. intermittent heparin infusion, concentration is great changed because the heparin has 30minutes half-period. researchers postulate that a constant therapeutic concentrations would be beneficial to continuous infusion than intermittent infusion.

Eligibility criteria:
inclusion criteria: * atrial fibrillation, radiofrequency catheter ablation scheduled exclusion criteria: * clinical trial denied

Keywords: continuous heparin infusion intermittent heparin infusion during catheter ablation
preoperative hfrt verses pulsar for locally advanced gej or proximal gastric adenocarcinoma

Conditions: Stomach Adenocarcinoma; Gastro-esophageal Junction Cancer

Summary: the goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-pd-1 immunotherapy. the trial is designed using a pick-the-winner strategy. the main questions it aims to answer are: 1. if the multimodal treatment will improve the pcr rate. 2. if the multimodal treatment can be performed safely. 3. hypofractionated radiotherapy (hfrt) or personalized hyperfractionated stereotactic adaptive radiotherapy (pulsar), which pattern of radiotherapy can better synergize with immunotherapy. participants will receive hfrt or pulsar for the primary lesion and positive lymph nodes, combined with capox and anti-pd-1 immunotherapy. then, reassessment will be performed within 4 weeks afterwards. for resectable participants, surgical resections will be performed. postoperative treatment will be determined by the investigators. for unresectable or inoperable participants, the subsequent treatment will be determined by investigators or mdt.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed adenocarcinoma of proximal stomach (g) or gastroesophageal junction (gej) (excluding siewert type i). * potentially resectable, ct3-4an+m0 or ct4bnanym0. * exclusion of peritoneal metastasis through laparoscopic exploration or fapi pet/ct. * the status of her2, mmr, eber is clear. * male or female. patient age ≥ 18 years and ≤ 75 years. * eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1. * physical state or organ function can tolerate the planned treatment of the study protocol. * no previous surgery or antitumor therapies, including chemotherapy, radiotherapy, or immunotherapy, were administered. * patients agree to sign written informed consent before recruitment. exclusion criteria: * pregnancy or breastfeeding women. * history of other malignancies within 5 years. * serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. * immunodeficiency disease or long-term using of immunosuppressive agents. * allergic to any component of the therapy. * any other condition or disease that is not suitable to take the therapy included in the protocol.

Keywords: radiotherapy pd-1 inhibitors chemotherapy locally advanced gastrectomy neoadjuvant hypofractionated radiotherapy
dermacyd ph_desilsty_fr (lactic acid) - photo evaluation - stay on frutal

Conditions: Hygiene

Summary: primary objective: to demonstrate the absence of photoirritation and potential photosensitization of the product dermacyd phdesilstyfr.


Eligibility criteria:
inclusion criteria: * phototype skin ii and iii integral skin test in the region * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion exclusion criteria: * lactation or pregnancy * use of antiinflammatory 30 days and/or immunossupression drugs until 3 months before volunteers selection * disease which can cause immunosuppresion, such as diabetes, hiv * concomitant use of photosensitivity drugs * history of sensitivity or photosensitivity with topic products * cutaneous active disease which can modify the study results * history or activity of photodermatosis * personal or family antecedents of cutaneous neoplasia photo induced * presence of injury precursor of cutaneous neoplasia, such as melanociticos nevus and actinic keratosis * intense exposure solar in the test region * use of new drugs and/or cosmetics during the study * previous participation in studies using the same product in test * relevant history or confirmation of alcohol or other drugs abuse * intolerance detected or suspected for some component of the sample tested * medecin or sponsor employees or their close family. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
transcoronary infusion of cardiac progenitor cells in patients with single ventricle physiology

Conditions: Hypoplastic Left Heart Syndrome; Single Ventricle; Heart Failure

Summary: hypoplastic left heart syndrome (hlhs) and related anomalies involved a single ventricle are characterized by hypoplasia of the left heart and the aorta with compromised systemic cardiac output. infants with the syndrome generally undergo a staged surgical approach in view of an ultimate fontan procedure. although long-term survival in patients with hlhs and related single ventricle physiology has improved markedly with advances in medical and surgical therapies, a growing number of infants will ultimately require heart transplantation for end-stage heart failure due to several potential disadvantages include a negative effect on right ventricular function, arrhythmia, additional volume load via regurgitation from the nonvalved shunt, and impaired growth of the pulmonary artery. risk factors for poor outcome of heart transplantation with hlhs and single ventricle physiology are older age at transplantation and previous fontan operation. new strategies are needed to improve the underlying transplant risks proper for the fontan failure patients. emerging evidence suggests that heart-derived stem/progenitor cells can be used to improved cardiac function in patients with ischemic heart disease. in this trial, the investigators aimed to test the safety and feasibility of intracoronary injection of autologous cardiac progenitor cells in patients with hlhs and related single ventricle anomalies and that could improve ventricular function at 3 months' follow up.

autologous cardiac progenitor cells are isolated from patients' own cardiac tissues obtained during palliative shunt procedure. patients will receive 0.3 million/kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.

Eligibility criteria:
inclusion criteria: * infants with hypoplastic left heart syndrome and related single ventricle anomalies undergoing first to third palliative shunt surgeries will be recruited into the study. * patients between 0 and 6 years of age are eligible if written informed consent can be obtained. exclusion criteria: * cardiogenic shock * eisenmenger syndrome * uncontrollable arrhythmia * severe chronic diseases * infections * cancer * unwillingness to participate

Keywords: cardiac progenitor cells cell therapy hypoplastic left heart syndrome single ventricle norwood sano modification glenn fontan
study to evaluate safety and immunogenicity of sub-unit adjuvanted influenza vaccine administered to elderly subjects, formulation 2011-2012

Conditions: Seasonal Influenza

Summary: this study will evaluate the safety and immunogenicity of a sub-unit, adjuvanted influenza vaccine administered to elderly subjects.


Eligibility criteria:
key inclusion criteria: * males and females volunteers of 65 years of age or older, mentally competent, willing and able to give written informed consent prior to study entry. * individuals able to comply with all the study requirements. * individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator. * written informed consent must be obtained for all the subjects before enrollment into the study after the nature of the study has been explained. key exclusion criteria: * individuals with any serious chronic or acute disease. * individuals with history of any anaphylactic reaction and/or serious allergic reaction following a vaccination. * individuals with known or suspected impairment/alteration of immune function. * individuals with known or suspected history of drug or alcohol abuse. * individuals with a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject. * individuals within the past 6 months, they have: had any seasonal or pandemic laboratory confirmed influenza disease; received any seasonal or pandemic influenza vaccine. * individuals with any acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days. * individuals that have experienced fever (i.e., axillary temperature ≥38°c) within the last 3 days of intended study vaccination. * individuals participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study. * individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines. * individuals who are part of study personnel or close family members conducting this study. * bmi \> 35 kg/m2.

Keywords: seasonal influenza, vaccine
presence and relapse rates in patients with alcohol use disorder using virtual reality

Conditions: Alcohol Dependence

Summary: investigation of the influence of the sense of presence during a virtual reality cue-exposure therapy (vr-cet) with alcohol-associated cues on craving and relapse rates. study group: abstinent patients (at least 18 years old) with a diagnosed alcohol dependence after completed inpatient withdrawal treatment in the the last 3 months. primary hypothesis: the experience of presence during a virtual presentation of alcohol in alcohol-dependent patients is associated with levels of craving for alcohol during vr-cet.


Eligibility criteria:
inclusion criteria: * age: 18-65 years * diagnosis of alcohol dependence according to icd-10 (f10.2) * completed in-patient withdrawal treatment during the last 3 months * history of alcohol craving, confrmed via craving questionnaires * able to provide written informed consent exclusion criteria: * substance dependence other than alcohol and nicotine * current alcohol intoxication (randomly tested via measurement of breath alcohol concentration) * unable to understand the study information, consent form or principles of the study * abstinence for less than 7 days or on-going consumption of alcohol * severe neuropsychiatric disorder, e.g., schizophrenia spectrum disorders, bipolar afective disorder or substantial cognitive impairment * somatic diseases for which vr is associated with risks, e.g. photosensitive epilepsy * acute suicidality or acute endangerment of others * concurrent pharmacological treatment targeting aud (i.e. benzodiazepines) or craving (i.e. acamprosate, disulfram, naltrexone, nalmefene)
a comparison of redrubber versus penrose drains

Conditions: Odontogenic Infection

Summary: all patients presenting to grady memorial hospital with an odontogenic (dental) infection that requires admission to the hospital and incision and drainage will be eligible for inclusion in this pilot study. the surgical method used for incision and drainage will be determined by the attending surgeon who will operate on the patient. the surgical procedure is a simple and universally standardized involving one or more small incisions in the mouth or in the upper neck and the placement of a drain(s) within the infected area to facilitate continued drainage of pus. subjects will be randomized to either a red rubber or penrose drain(s). the drains are placed through the mouth or upper neck depending on the location of the infection and typically remain in place until the drainage has stopped (several days). all drains are secured with a single stitch through the gum or skin. the drain(s) will be removed bedside by removing a single suture and gently withdrawing the drain. the timing of this is determined by the clinical picture although this typically occurs within the first week. this is not a painful procedure. currently some surgeons place red rubber drains which, after placement, allow the infection not only to drain but also be irrigated with saline both during the surgery and in the immediate post-operative period. other surgeons place penrose drains, which, after placement, continue to allow the infection to drain but cannot be irrigated. red rubber drains require daily irrigation and as such are labor intensive. furthermore, drains that are irrigated may continue to drain the saline irrigant in the many hours after irrigation that upon clinical inspection may be difficult to distinguish from sero-sanguinous (pus) drainage. it is daily inspection of the drainage (or lack thereof) which determines the appropriate time to remove the drain(s). this in turn may influence time to discharge and ultimately hospital costs


Eligibility criteria:
inclusion criteria: * age 16 and older exclusion criteria: * none

Keywords: drainage irrigation
neighborhoods and cvd risk in a multiethnic cohort - ancillary to mesa

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Atherosclerosis

Summary: to investigate if neighborhood characteristics are related to disease risk in a multiethnic cohort.

background: recent epidemiologic studies have found that living in socioeconomically disadvantaged neighborhoods is associated with increased prevalence and incidence of coronary heart disease, even after controlling for measures of personal income, education, and occupation. although this suggests that features of neighborhoods may be relevant to cardiovascular risk, important questions remain regarding whether the associations observed reflect causal processes. two important unresolved issues are the role of selection factors in generating these associations and the need to identify the specific characteristics of neighborhoods that are relevant. design narrative: the study uses publicly available and newly collected neighborhood data linked to the multi-ethnic study of atherosclerosis (mesa) to: (1) examine the relationship between neighborhood socioeconomic characteristics and the prevalence and progression of subclinical atherosclerosis; (2) examine associations of neighborhood socioeconomic characteristics with specific individual-level factors which may mediate neighborhood differences in disease risk; (3) develop measures of specific characteristics of neighborhood environments (such as measures of resource availability, neighborhood social cohesion and neighborhood stress) and examine their relation to selected individual-level risk factors; (4) determine if these specific neighborhood characteristics explain differences in cardiovascular risk between socioeconomically advantaged and socioeconomically disadvantaged neighborhoods; and (5) examine if neighborhood characteristics contribute to race/ethnic differences in cardiovascular risk. measures of neighborhood attributes will be based on year 2000 census data, surveys of area residents, and the use of gis methods to link data on area resources to mesa neighborhoods. the examination of subclinical disease as outcomes avoids problems related to selection of persons into neighborhoods based on their health status. the project will use two innovative approaches (residential surveys and ecometric techniques and gis-based methods) to develop direct measures of specific neighborhood attributes in order to test their relationship to disease risk. confirming that specific features of neighborhoods are causally related to disease would have important implications for prevention.

Eligibility criteria:
no eligibility criteria
pharmacokinetic study to compare absorption of budesonide/formoterol easyhaler and symbicort turbuhaler

Conditions: Asthma

Summary: the purpose of this study is to compare budesonide/formoterol easyhaler test products with the marketed product symbicort turbuhaler in terms of the drug absorbed into the bloodstream.


Eligibility criteria:
inclusion criteria: * written informed consent obtained * body mass index \> 19 and \< 30kg/m2, weight at least 50 kg * good general health ascertained by detailed medical history, and laboratory and physical examinations exclusion criteria: * evidence of a clinically significant cardiovascular, renal, hepatic, haematological, gi, pulmonary, metabolic-endocrine, neurological or psychiatric disease * any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during a study. * known hypersensitivity to the active substance(s) or the excipient of the drug * pregnant and lactating females
ologen (oculusgen)-glaucoma and pterygium historical control study in china zhong-shan hospital

Conditions: Glaucomas; Pterygium

Summary: the purpose of this study is to determine whether the oculusgen collagen matrix are effective and safe to implant as an aid of glaucoma surgery.

ologen (oculusgen) collagen matrix is a porous, scaffold matrix. it is to be implanted on the top of the scleral flap and beneath the conjunctiva and tenon's capsule at the end of trabeculectomy. the pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. the space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. immediately after implantation, the collagen matrix is absorbed with the aqueous humor that bring a certain pressure press on the top of scleral flap which makes the dynamic balance for the aqueous system to keep the iop in the right side. the collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (iop).

Eligibility criteria:
inclusion criteria: 1. age 18 years or over 2. patient able to cooperate with study procedures and able to perform tests reliably 3. patient willing to sign informed consent 4. patient able and willing to complete postoperative follow-up requirements 5. glaucoma：one/both eyes are affected by glaucoma 6. pterygium： patient with pterygium exclusion criteria: * known allergic reactions to collagen

Keywords: glaucoma pterygium collagen matrix oculusgen trabeculectomy anti scarring pterygium recurrence tissue engineering aeon astron ologen
study of carboplatin/gemcitabine plus bevacizumab in advanced lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: * this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added * the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen) * all patients receive all three drugs; there is no placebo

* patients with advanced (stage iv, and stage iiib with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible. * patients with brain metastases, squamous histology, or hemoptysis are excluded. * all patients must give informed consent. * schema gemcitabine 1250 mg/m2 iv day 1,8 carboplatin auc 5 iv day 1 bevacizumab 15 mg/kg iv day 1 repeated every 21 days for 6 cycles

Eligibility criteria:
inclusion criteria: * histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy * stage iv disease or stage iiib with a malignant pleural effusion * measurable or evaluable disease * performance status 0 or 1 (ecog) * adequate renal, hepatic, and bone marrow function * adequate recovery from previous surgery or radiotherapy * informed consent exclusion criteria: * brain metastases * squamous (epidermoid) histology * hemoptysis * central airway disease * pancoast tumors * previous chemotherapy or biologic therapy for lung cancer * prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical cis * pregnant or nursing women